Fig. 6. Biomimetic NIR-I/II FPs for multicolor in vivo imaging.

a Schematic of the biomimetic NIR-I FPs and NIR-II FPs constructed via biomimetic strategy. b Schematic of the NIR-I/II multi-wavelength excitation imaging device. c) Gel electrophoresis analysis of the HSA@IR-808 (NIR-I FPs) and HSA@CO-1080 (NIR-II FPs) (n = 4 independent experiment). d Fluorescence intensities of the HSA@IR-808 FPs and HSA@CO-1080 FPs under 808 nm and 1064 nm excitation, respectively (n = 10 independent samples per group). e Dual-color lymph node imaging and colocalization using HSA@IR-808 FPs (intradermal footpad or tail injection) and HSA@CO-1080 FPs (intradermal footpad injection) (n = 3 independent mice). f Co-localization imaging of tumor-associated sentinel lymph nodes using HSA@IR-808 FPs and HSA@CO-1080 FPs (n = 3 independent mice). g Pathological images of the tumor-draining sentinel lymph node (n = 3 independent mice). h Dual-color imaging of lymphatic system and blood vessels using HSA@IR-808 and HSA@CO-1080 FPs (n = 3 independent mice). i Dual-color metabolic behavior imaging using the β-LG@IR-780 FPs and HSA@CO-1080 FPs. j Multicolor in-vivo imaging using HSA@Cy5, β-LG@IR-780, RENPs (NaYbF₄:Ce, Er@NaYF₄:Gd, Yb@PAA), and HSA@CO-1080 FPs under different excitation wavelengths (660 nm, 808 nm, 980 nm, and 1064 nm) and collection wavelengths (n = 3 independent mice). Note: the injection concentration of the RENPs probe was 250 mg/ml (> 1500 nm collection), the injection concentration of the HSA@Cy5 probe was 200 μM ( > 700 nm collection), and the injection concentration of the β-LG@IR-780, HSA@IR-808, and HSA@CO-1080 probe was 600 μM ( > 1200 nm collections). All scale bar lengths represent 1 cm. Some schematic diagrams were designed using BioRender software. Source data are provided as a Source Data file.